<DOC>
	<DOCNO>NCT01687296</DOCNO>
	<brief_summary>This multicentre , randomize , double-blind , double-dummy , active-controlled , parallel-group study determine efficacy safety nebulized fluticasone propionate 1mg twice daily compare oral prednisone administer 7 day Chinese pediatric adolescent subject ( age 4 16 year ) acute exacerbation asthma</brief_summary>
	<brief_title>Nebulized Fluticasone Propionate VS Oral Prednisone Chinese Pediatric Adolescent Subjects With Acute Exacerbation Asthma</brief_title>
	<detailed_description>This multicentre , randomize , double-blind , double-dummy , active-controlled , parallel-group study determine efficacy safety nebulized fluticasone propionate ( FP ) 1mg twice daily compare oral prednisone administer 7 day Chinese pediatric adolescent subject ( age 4 16 year ) acute exacerbation asthma . This study support registration FP Nebules treat Chinese pediatric adolescent subject ( age 4 16 year ) acute exacerbation asthma China . At least 250 subject , age 4-16 year old , diagnose acute exacerbation asthma presentation , eligible take part study meet inclusion criterion . They randomly assign ratio 1:1 one follow treatment group 7 day : FP Nebules 2×0.5mg/2ml twice daily/Placebo tablet daily ; Or , Oral prednisone tablet daily ( 2mg/kg.day , 40mg/day 4 day , 1mg/kg.day half original dose , 20mg/day 3 day ) / Placebo Nebules 2×2ml 0.9 % saline twice daily . While subject give Salbutamol Nebules / MDI relief symptom . After randomization ( visit 1 ) , follow visit Day5 ( visit 2 ) Day8 ( visit 3 ) , follow-up phone call ( visit4 ) happen two week post treatment Day 21 collection adverse event . The primary endpoint mean morning PEF diary card treatment assessment period . The secondary endpoint include subject derive data ( symptom score ) , even PEF diary card , use rescue medication , clinic assessment pulmonary function ( FEV1 , FVC ) , clinical score index , patient/parent investigator global evaluation , use rescue medication trial . Safety endpoint include AEs , vital sign , oropharyngeal examination , laboratory test ( haematology , urinalysis , chemistry ) . The subject assess compliance completion diary card .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Chinese male female pediatric adolescent subject age 4 16 year , inclusive Subjects establish diagnosis asthma The definition asthma . According Chinese Guideline diagnosis optimal management asthma child [ Respiratory branch pediatric society , Chinese Medical . Association . 2008 , revise version ] , subject diagnose meeting criterion . The diagnosis criterion list protocol . The severity acute exacerbation asthma define PEF 50 % 75 % predict via peak flow meter , clinical score index ≥2 . The clinical scoring index represent sum score four sign : respiratory rate ( 0=low 3=high , dependent age ) , wheeze ( 0=none 3=severe ) , inspiration/expiration ratio ( 0=2:1 3=1:3 ) , accessory muscle ( 0=none 3=marked use ) . Subjects properly use miniwright peak flow meter , nebulizer MDI with/without spacer , accurately complete diary card parental assistance , require . Subjects ' parents/guardians willing give write informed consent . Exclusion criterion : Severe respiratory dysfunction . History mechanical ventilation due respiratory failure . Admission hospital due respiratory disease within previous 2 week , include asthmatic exacerbation . Clinical lab evidence serious , uncontrolled systemic disease presence disease likely interfere objective study , pulmonary cystic fibrosis bronchopulmonary dysplasia . Known suspected hypersensitivity glucocorticosteroids β2 agonist . Clinical visual evidence oral candidiasis Visit1 . Use medication Table 1 accord follow defined time interval prior presentation . The list provide protocol .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>PEF</keyword>
	<keyword>inhale</keyword>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>safety</keyword>
	<keyword>prednisone</keyword>
	<keyword>acute exacerbation</keyword>
	<keyword>asthma</keyword>
	<keyword>efficacy</keyword>
</DOC>